FindTrial
Sign In

Sparsentan_DF2

DRUG3 trials

Sponsors

Travere Therapeutics Inc.

Conditions

Focal segmental glomerulosclerosis (FSGS)Immunoglobulin A Nephropathy (IgAN)Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)

Phase 2

A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK)
RecruitingCTIS2023-505497-14-00
Travere Therapeutics Inc.Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)
Start: 2021-12-09Target: 27Updated: 2025-09-25

Phase 3

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)
Active, not recruitingCTIS2023-505495-30-00
Travere Therapeutics Inc.Immunoglobulin A Nephropathy (IgAN)
Start: 2019-02-01Target: 162Updated: 2025-11-07
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
Active, not recruitingCTIS2023-505494-32-00
Travere Therapeutics Inc.Focal segmental glomerulosclerosis (FSGS)
Start: 2018-10-15Target: 116Updated: 2025-12-18